Robert Stone and Marcel van den Brink at the Progress, Potential, And Possibilities podcast – City of Hope
“Robert Stone and Dr. Marcel van den Brink recently joined the Progress, Potential, And Possibilities podcast discussing key topics such as City of Hope’s expanding national footprint, access to advanced care, global collaboration and diversity in clinical trials, in addition to providing detail on some of the latest advances in research at City of Hope.
‘Value and access, and access to the cutting-edge clinical trials and the research that’s happening at centers like City of Hope, those two concepts are linked by the concept that access means survival.
And the greatest definition of value, the one that cancer patients care the most about, is survival. Conversations that are happening in the policy halls and in insurance discussions about value in healthcare today are too often limited to discussions about cost savings.
We should start the value conversation by focusing on the benefit to society of saving a life,’ says Robert Stone, CEO of City of Hope and the Helen and Morgan Chu Chief Executive Officer Distinguished Chair.
Listen and watch the interview for more.”
More posts featuring .
Robert Stone serves as the Chief Executive Officer and the Helen and Morgan Chu Chief Executive Officer Distinguished Chair at the City of Hope, a leading cancer research and treatment center.
He has a Juris Doctorate from the University of Chicago and a bachelor’s degree in Political Science from the University of Redlands. Stone’s leadership focuses on expanding access to cancer care and advancing transformative research in oncology.
Marcel van den Brink, M.D., Ph.D., president of City of Hope Cancer Center and National Medical Center in Los Angeles, holds the Deana and Steve Campbell Chief Physician Executive Distinguished Chair.
A global leader in bone marrow transplantation (BMT), the microbiome, and cancer immunotherapy, he specializes in immune reconstitution, graft-versus-host disease, and the microbiome’s role in cancer treatment.
His research has advanced BMT by reducing toxicity, lowering recurrence rates, and translating laboratory discoveries into improved therapies worldwide.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023